Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company’s lead program is now PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. This new capital, combined with existing cash, is expected to fund clinical operations through major 2026 milestones, including Phase 2 data in endometrial cancer and a Phase 1b trial in breast cancer.

Financial results for the full year 2025 reflect a period of significant cost reduction and restructuring. R&D expenses dropped to $11.0 million from $18.6 million in 2024, while G&A costs fell to $11.3 million. These decreases were largely driven by lower personnel and manufacturing costs, alongside reduced spending on facilities and laboratory supplies.

The company reported a net loss of $21.1 million for 2025, an improvement over the $30.2 million loss recorded the previous year. As of December 31, 2025, Sensei Biotherapeutics Inc. (NASDAQ:SNSE) held $21.2 million in cash and marketable securities, down from $41.3 million at the end of 2024. However, the subsequent $200 million financing significantly supports the balance sheet to back the accelerated development of its oncology pipeline.

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is a clinical-stage biotechnology company that treats cancer through multi-node inhibition of critical oncogenic pathways.

While we acknowledge the potential of SNSE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.